Evidence map›Paper›PMID 40447761›Full record

ArticleScientific reports2025

Changes in metabolic syndrome status and risk of chronic kidney disease over a decade of follow-up in the Iranian population.

Maryam Kabootari, Reza Habibi Tirtashi, Atefeh Amouzegar, Safdar Masoumi, Fereidoun Azizi, Atieh Amouzegar

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam Kabootari *Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Reza Habibi Tirtashi *Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Atefeh AmouzegarFiroozgar Clinical Research Development Center (FCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Safdar MasoumiEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No. 24, Aerabi St, Daneshjoo Blv, Velenjak, P.O. Box 19395-4763, Tehran, Iran.
Fereidoun AziziEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No. 24, Aerabi St, Daneshjoo Blv, Velenjak, P.O. Box 19395-4763, Tehran, Iran.
Atieh AmouzegarEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No. 24, Aerabi St, Daneshjoo Blv, Velenjak, P.O. Box 19395-4763, Tehran, Iran. Amouzegar@endocrine.ac.ir.

Funding

Shahid Beheshti University of Medical Sciences 43008999-2
6 · The paper itself

Abstract

This study assessed the effect of MetS status changes over 3 years on the long-term risk of CKD. The analysis included 5686 participants aged ≥ 20 years without pre-existing CKD (57.5% women), followed for a median of 15 years. Participants were classified into 4 groups according to their baseline MetS status and its changes: stable MetS-free, MetS-developed, MetS-recovered, and stable MetS. Hazard ratios (HR) of incident CKD with a 95% confidence interval (CI) were calculated using Cox's proportional hazard models, adjusted for age, sex, education, physical activity, smoking status, and MetS components. During follow-up, a total of 1360 CKD (women = 881) occurred. Compared to the stable MetS-free group, the stable MetS [HR 1.34 (95% CI 1.06-1.71)] and MetS-developed [HR 1.22 (95% CI 1.03-1.45)] groups had a higher CKD risk. Conversely, recovery from MetS was not significantly associated with CKD risk. However, when using the stable MetS group as the reference, recovery from MetS was linked to a significant 23% lower CKD risk. Considering MetS component changes, persistent elevated blood pressure, elevated blood glucose, and high triglyceride, as well as recovered central obesity and new-onset high triglyceride, significantly impacted CKD incidence. In conclusion, persistent or newly developed MetS increased CKD risk, whereas recovery from MetS reduced the risk compared to persistent MetS.

Indexed as

Metabolic SyndromeRenal Insufficiency, ChronicAdultAgedFemaleFollow-Up StudiesHumansIncidenceIranMaleMiddle AgedProportional Hazards ModelsRisk FactorsChanges in MetS statusChronic kidney diseaseMetabolic syndrome

Identifiers

PMID40447761
PMCPMC12125341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.